Recently Expired Drugs

1. Adasuve patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8387612 NOVA PNEUMA Self-contained heating unit and drug-supply unit employing same
Oct, 2026

(28 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Dec 21, 2015

Drugs and Companies using LOXAPINE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: NA

Dosage: POWDER

More Information on Dosage

ADASUVE family patents

Family Patents

2. Avycaz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612087 ABBVIE Heterocyclic compounds as inhibitors of beta-lactamases
Nov, 2026

(8 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-738) Jun 22, 2019
New Chemical Entity Exclusivity(NCE) Feb 25, 2020
Generating Antibiotic Incentives Now(GAIN) Feb 25, 2025
New Patient Population(NPP) Jan 26, 2027

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 25 February, 2019

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER

How can I launch a generic of AVYCAZ before its drug patent expiration?
More Information on Dosage

AVYCAZ family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Bevyxxa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598276 PORTOLA Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(12 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555023 PORTOLA Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(13 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: 23 June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: Prophylaxis of pulmonary embolism

Dosage: CAPSULE

More Information on Dosage

BEVYXXA family patents

Family Patents

4. Emblaveo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612087 ABBVIE Heterocyclic compounds as inhibitors of beta-lactamases
Nov, 2026

(8 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 07, 2028
Generating Antibiotic Incentives Now(GAIN) Feb 07, 2033

Drugs and Companies using AVIBACTAM SODIUM; AZTREONAM ingredient

Market Authorisation Date: 07 February, 2025

Treatment: NA

Dosage: POWDER

More Information on Dosage

EMBLAVEO family patents

Family Patents

5. Entresto patent expiration

ENTRESTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9388134 NOVARTIS Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2026

(12 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 07, 2020
New Patient Population(NPP) Oct 01, 2022
Pediatric Exclusivity(PED) Apr 01, 2023
M(M-82) Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: Treatment of heart failure

Dosage: TABLET

How can I launch a generic of ENTRESTO before its drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

6. Entresto Sprinkle patent expiration

ENTRESTO SPRINKLE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9388134 NOVARTIS Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2026

(12 days ago)




Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 12 April, 2024

Treatment: Treatment of heart failure

Dosage: CAPSULE, PELLETS

More Information on Dosage

ENTRESTO SPRINKLE family patents

Family Patents

7. Eohilia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8975243 TAKEDA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(11 days ago)

US8497258 TAKEDA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(11 days ago)

US8679545 TAKEDA Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(11 days ago)

US11413296 TAKEDA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(11 days ago)

US11197822 TAKEDA Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(11 days ago)

US9119863 TAKEDA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(11 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 09, 2027
Orphan Drug Exclusivity(ODE-466) Feb 09, 2031

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 09 February, 2024

Treatment: Treatment of eosinophilic esophagitis

Dosage: SUSPENSION

How can I launch a generic of EOHILIA before its drug patent expiration?
More Information on Dosage

EOHILIA family patents

Family Patents

8. Genvoya patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8981103 GILEAD Stable crystal of 4-oxoquinoline compound
Oct, 2026

(25 days ago)

US7635704 GILEAD Stable crystal of 4-oxoquinoline compound
Oct, 2026

(25 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 25, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Dosing Schedule(D-173) Dec 10, 2021

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of GENVOYA before its drug patent expiration?
More Information on Dosage

GENVOYA family patents

Family Patents

9. Gilotrif patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539258 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
Nov, 2026

(11 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 12, 2018
New Indication(I-730) Apr 15, 2019
Orphan Drug Exclusivity(ODE-50) Jul 12, 2020
New Indication(I-763) Jan 12, 2021
Orphan Drug Exclusivity(ODE) Apr 15, 2023
Orphan Drug Exclusivity(ODE-115) Apr 15, 2023
Orphan Drug Exclusivity(ODE-230) Jan 12, 2025
M(M-276) Apr 07, 2025
Pediatric Exclusivity(PED) Oct 07, 2025

Drugs and Companies using AFATINIB DIMALEATE ingredient

NCE-1 date: 07 October, 2024

Market Authorisation Date: 12 July, 2013

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy

Dosage: TABLET

How can I launch a generic of GILOTRIF before its drug patent expiration?
More Information on Dosage

GILOTRIF family patents

Family Patents

10. Hernexeos patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US12171739 BOEHRINGER INGELHEIM N4-Phenyl-Quinazoline-4-Amine Derivatives And Related Compounds As Erbb Type I Receptor Tyrosine Kinase Inhibitors For The Treatment Of Hyperproliferative Diseases
Nov, 2026

(5 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 08, 2030

Drugs and Companies using ZONGERTINIB ingredient

NCE-1 date: 08 August, 2029

Market Authorisation Date: 08 August, 2025

Treatment: NA

Dosage: TABLET

More Information on Dosage

HERNEXEOS family patents

Family Patents

11. Horizant patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8026279 AZURITY Crystalline form of γ-aminobutyric acid analog
Nov, 2026

(10 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-652) Jun 06, 2015
New Chemical Entity Exclusivity(NCE) Apr 06, 2016
Orphan Drug Exclusivity(ODE) Jun 06, 2019
Orphan Drug Exclusivity(ODE-25) Jun 06, 2019

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

NCE-1 date: 07 April, 2015

Market Authorisation Date: 13 December, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of HORIZANT before its drug patent expiration?
More Information on Dosage

HORIZANT family patents

Family Patents

12. Lyrica Cr patent expiration

LYRICA CR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945620 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(18 days ago)

US10022447 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(18 days ago)

US9144559 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(18 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 11, 2020
Pediatric Exclusivity(PED) Apr 11, 2021

Drugs and Companies using PREGABALIN ingredient

Market Authorisation Date: 11 October, 2017

Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of LYRICA CR before its drug patent expiration?
More Information on Dosage

LYRICA CR family patents

Family Patents

13. Orkambi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9216969 VERTEX Modulators of ATP-binding cassette transporters
Nov, 2026

(12 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216969 VERTEX Modulators of ATP-binding cassette transporters
Nov, 2026

(12 days ago)

US8741933 VERTEX Modulators of ATP-binding cassette transporters
Nov, 2026

(12 days ago)

US7973038 VERTEX Modulators of ATP-binding cassette transporters
Nov, 2026

(12 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 02, 2025
Pediatric Exclusivity(PED) Jun 13, 2028
New Chemical Entity Exclusivity(NCE) Jul 02, 2020
M(M-218) Jan 25, 2021
New Product(NP) Aug 07, 2021
Orphan Drug Exclusivity(ODE-93) Jul 02, 2022
Orphan Drug Exclusivity(ODE) Sep 28, 2023
Orphan Drug Exclusivity(ODE-123) Sep 28, 2023
Orphan Drug Exclusivity(ODE-195) Aug 07, 2025
New Strength(NS) Sep 02, 2025
Generating Antibiotic Incentives Now(GAIN) Jan 02, 2028
M(M-14) Dec 13, 2027
Orphan Drug Exclusivity(ODE-408) Sep 02, 2029

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

NCE-1 date: 03 July, 2019

Market Authorisation Date: 02 September, 2022

Treatment: Treatment of cystic fibrosis in a patient age 1-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor and ivacaftor; Treatment of cystic fibrosis in a patient age 2-5 ye...

Dosage: GRANULE; TABLET

More Information on Dosage

ORKAMBI family patents

Family Patents

14. Perseris Kit patent expiration

PERSERIS KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11110093 INDIVIOR Sustained release small molecule drug formulation
Nov, 2026

(15 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 27, 2021

Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 27 July, 2018

Treatment: Treating schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

PERSERIS KIT family patents

Family Patents

15. Signifor Lar Kit patent expiration

Can you believe SIGNIFOR LAR KIT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7759308 RECORDATI RARE Microparticles comprising somatostatin analogues
Oct, 2026

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2017
New Product(NP) Dec 15, 2017
New Indication(I-785) Jun 29, 2021
Orphan Drug Exclusivity(ODE) Dec 15, 2021
Orphan Drug Exclusivity(ODE-81) Dec 15, 2021
Orphan Drug Exclusivity(ODE-268) Jun 29, 2025

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

NCE-1 date: 14 December, 2016

Market Authorisation Date: 29 June, 2018

Treatment: NA

Dosage: FOR SUSPENSION

More Information on Dosage

SIGNIFOR LAR KIT family patents

Family Patents

16. Stribild patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7635704 GILEAD Stable crystal of 4-oxoquinoline compound
Oct, 2026

(25 days ago)

US8981103 GILEAD Stable crystal of 4-oxoquinoline compound
Oct, 2026

(25 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 27, 2015
New Chemical Entity Exclusivity(NCE) Aug 27, 2017
New Indication(I-704) Dec 17, 2017
New Patient Population(NPP) Jan 27, 2020

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 27 August, 2012

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of STRIBILD before its drug patent expiration?
More Information on Dosage

STRIBILD family patents

Family Patents

17. Syfovre patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9056076 APELLIS Method of treating age-related macular degeneration comprising administering a compstatin analog
Oct, 2026

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 22, 2026
New Chemical Entity Exclusivity(NCE) May 14, 2026

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: 14 May, 2025

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan

Dosage: SOLUTION

More Information on Dosage

SYFOVRE family patents

Family Patents

18. Synribo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6987103 TEVA Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
Oct, 2026

(25 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 26, 2017
Orphan Drug Exclusivity(ODE) Oct 26, 2019
Orphan Drug Exclusivity(ODE-32) Oct 26, 2019

Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient

NCE-1 date: 26 October, 2016

Market Authorisation Date: 26 October, 2012

Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml)

Dosage: POWDER

How can I launch a generic of SYNRIBO before its drug patent expiration?
More Information on Dosage

SYNRIBO family patents

Family Patents

19. Tukysa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7452895 SEAGEN Quinazoline analogs as receptor tyrosine kinase inhibitors
Nov, 2026

(4 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 17, 2025
New Indication(I-906) Jan 19, 2026
Orphan Drug Exclusivity(ODE-309) Apr 17, 2027
New Indication(I-1003) Oct 07, 2029
Orphan Drug Exclusivity(ODE-422) Jan 19, 2030

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET

More Information on Dosage

TUKYSA family patents

Family Patents

20. Uptravi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7205302 ACTELION Heterocyclic compound derivatives and medicines
Oct, 2026

(20 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2020
Orphan Drug Exclusivity(ODE) Dec 21, 2022
Orphan Drug Exclusivity(ODE-106) Dec 21, 2022
New Patient Population(NPP) May 23, 2029
New Strength(NS) May 23, 2029
Pediatric Exclusivity(PED) Nov 23, 2029

Drugs and Companies using SELEXIPAG ingredient

Market Authorisation Date: 29 July, 2021

Treatment: Method of treating pulmonary arterial hypertension comprising administering a pharmaceutical composition comprising selexipag

Dosage: POWDER; TABLET

How can I launch a generic of UPTRAVI before its drug patent expiration?
More Information on Dosage

UPTRAVI family patents

Family Patents

21. Vitekta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8981103 GILEAD Stable crystal of 4-oxoquinoline compound
Oct, 2026

(25 days ago)

US7635704 GILEAD Stable crystal of 4-oxoquinoline compound
Oct, 2026

(25 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017
New Product(NP) Sep 24, 2017

Drugs and Companies using ELVITEGRAVIR ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 24 September, 2014

Treatment: Treatment of hiv infection

Dosage: TABLET

More Information on Dosage

VITEKTA family patents

Family Patents

22. Xeglyze patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7812163 LNHC Methods and compositions for controlling ectoparasites
Oct, 2026

(23 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 24, 2025

Drugs and Companies using ABAMETAPIR ingredient

NCE-1 date: 24 July, 2024

Market Authorisation Date: 24 July, 2020

Treatment: Topical treatment of head lice infestation in patients 6 months of age and older

Dosage: LOTION

More Information on Dosage

XEGLYZE family patents

Family Patents

23. Zelboraf patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7504509 HOFFMANN LA ROCHE Compounds and methods for development of Ret modulators
Oct, 2026

(29 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 17, 2016
Orphan Drug Exclusivity(ODE) Aug 17, 2018
Orphan Drug Exclusivity(ODE-13) Aug 17, 2018
M(M-184) Aug 31, 2019
New Indication(I-757) Nov 06, 2020
Orphan Drug Exclusivity(ODE-158) Nov 06, 2024

Drugs and Companies using VEMURAFENIB ingredient

NCE-1 date: 18 August, 2015

Market Authorisation Date: 17 August, 2011

Treatment: NA

Dosage: TABLET

More Information on Dosage

ZELBORAF family patents

Family Patents